ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2681

Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

Jenny Brouwer1,2, Johanna MW Hazes1, Joop SE Laven2 and Radboud JEM Dolhain1, 1Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Fertility, Nonsteroidal antiinflammatory drugs (NSAIDs), prednisolone, prednisone and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months.  During this period RA often cannot be treated optimally. As a result, a longer TTP may result in higher chance of permanent joint damage, with a negative impact on social roles. Thus far, no studies on possible causes of the prolonged TTP in RA patients have been reported. In order to optimize care for these women, we aimed to identify clinical factors associated with a prolonged TTP in RA patients.

Methods: From 2002 until 2010, a nationwide prospective cohort study on pregnancy in RA patients (PARA study) was performed. Women with RA according to the 1987 American College of Rheumatology (ACR) criteria were included preconceptionally or during first trimester. All preconceptionally included women were actively trying to become pregnant. To study the effect of various disease characteristics and medications on the TTP, we performed a multivariable Cox regression analysis.

Results: Two-hundred-forty-five patients were included. The mean age was 31.3±3.9 years. The TTP was longer than 12 months in 42% of patients, of whom 40 women(16%) had not gotten pregnant during the follow up period. A longer TTP was related to various variables. Hazard ratios for occurrence of pregnancy were 0.96 (95%CI 0.92-1.00) per year increase in age; 0.52 (0.38-0.70) for nulliparity; 0.81 (0.71-0.93) per point increase in disease activity score (DAS28); 0.61 (0.45-0.83) for preconceptional prednisone use; and 0.66 (0.46-0.94) for non-steroidal anti-inflammatory drug (NSAID) use. Eighty-five patients used prednisone during the preconceptional period. The impact of prednisone use on TTP was dose-dependent, with a significant longer TTP when the daily dose was higher than 7.5 mg. TTP was not affected by smoking, disease duration, rheumatoid factor, anti-citrullinated protein antibodies, past methotrexate use, and preconceptional sulfasalazine use.

Conclusion: TTP in female RA patients is longer if patients are older or nulliparous, have higher disease activity scores, use NSAIDs or use prednisone in a daily dose higher than 7.5 mg daily. Treatment strategies during the preconceptional period should try to maximize suppression of disease activity, taking account of possible negative effects of NSAIDs use and use of higher doses of prednisone.

Disclosures: This study was funded by the Dutch Arthritis Foundation (Reumafonds).


Disclosure:

J. Brouwer,
None;

J. M. Hazes,
None;

J. S. Laven,
None;

R. J. Dolhain,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-fertility-in-women-with-rheumatoid-arthritis-influence-of-disease-activity-and-medication-use/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology